Phaseline

Companies › Carna Biosciences

Carna Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AS-1763 (docirbrutinib)
BTK inhibitor
BTKPhase 1B-cell MalignancySep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05602363AS-1763 (docirbrutinib)Phase 1B-cell MalignancyOncologySep 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

BTK (1)

Companies with the same targets

Sanofi BeOne Medicines Eli Lilly AstraZeneca Guangzhou Lupeng Pharmaceutical Company Zenas BioPharma (USA) Merck & Co. (MSD) Acerta Pharma Beijing InnoCare Pharma Tech Dizal Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.